Joint venture between Mobidiag and Autobio Diagnostics will
commercialise Novodiag® platform and selected
infectious disease assays in the Greater China territory
ESPOO, Finland & ZHENGZHOU, China–(BUSINESS WIRE)–#IVD–Mobidiag Ltd., a commercial stage molecular diagnostics company
addressing the spread of antimicrobial resistance, today announces the
launch of Automobi Molecular Diagnostics Co., Ltd (‘Automobi’), the
joint venture (‘JV’) between Mobidiag and Autobio Diagnostics
(‘Autobio’), one of the leading clinical diagnostics companies in China.
Automobi is responsible for commercialising the Novodiag®
platform and selected infectious disease assays in the Greater China
Automobi’s initial activities will include the registration of the
Novodiag® platform and first assays with the National Medical
Products Administration (NMPA, former CFDA). Automobi will also
establish local facilities in China to manufacture certain Novodiag®
components and disposables, for the Greater China territory.
Tuomas Tenkanen, CEO of Mobidiag, said “We are very excited to
announce the official launch of Automobi. We have found the ideal
partner in Autobio and are confident that together we will be able to
bring easy-to-operate, multi-target molecular diagnostics and innovative
syndromic diagnostic panels to the growing Chinese market with
Yongjun Miao, Chairman of Autobio said “We are confident of
the combined multiplex real-time PCR together with microarray
technologies that applied in IVD diagnostics of infectious diseases,
allowing sample-to-result analysis in a disposable cartridge. We will
work jointly to complete the registration required by local regulations
with the aim of introducing the market with better products and serving
human health with better assays.”
As previously announced
in December 2018, Mobidiag and Autobio jointly agreed to invest €12.3m
to establish Automobi in China. Autobio is investing €8m in cash to hold
65%, and Mobidiag is investing €4.3m to hold 35%. Under the terms of the
partnership, Automobi acquired an exclusive license from Mobidiag to
commercialise the Novodiag® platform and selected human
infectious disease assays (excluding sepsis) for China.
In December 2018, Autobio invested €10m in Mobidiag. These funds are
being used to grow the Company’s product portfolio, accelerate the
development of further assays for the Novodiag® system and
enhance its manufacturing capabilities, as well as to further facilitate
Mobidiag’s commercial expansion.
Notes to editors
Automobi Molecular Diagnostics
Automobi is a joint venture established by Autobio and Mobidiag in 2019.
The initial activities plan include the Novodiag® platform registration
and sales and marketing in the Greater China territory. Automobi will
also finance the establishment of local facilities in China to
manufacture some Novodiag® components and disposables.
Automobi is located in Zhengzhou city, Henan Province, China.
About Mobidiag Ltd
Mobidiag is a commercial stage, fast growing molecular diagnostics
company whose fast, cost-effective, widely applicable and robust
technology makes the power of molecular diagnostics available to address
the spread of antimicrobial resistance (AMR) by rapid detection of
pathogens and their potential resistance to antibiotics. Through its
Amplidiag® and Novodiag® solutions, Mobidiag
offers a comprehensive range of molecular diagnostic solutions for the
detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in
France, UK and Sweden. To learn more, visit www.mobidiag.com
About Autobio Diagnostics Co., Ltd.
Founded in 1998, Autobio has become one of the leading clinical
diagnostics companies in China. Autobio specializes in research &
development, production, marketing and service of clinical diagnostic
products, including immunoassay, microbiology and biochemical products.
Autobio provides comprehensive solutions for medical laboratories. Learn
About the Novodiag® platform
platform is an innovative molecular diagnostics solution allowing
fully automated detection of infectious diseases, including antibiotic
resistances. The platform combines real-time PCR and microarray
technologies, to allow direct analysis of samples placed in a disposable
cartridge. It also allows for comprehensive screening of multiple or
single pathogens within approximately one hour, allowing clinicians to
be better informed when making time-critical decisions, helping to
deliver early treatments and avoid the spread of infection.
Dorothee Allard, Marketing Communications
T : +33 (0)1 55 25 17 13
Autobio Diagnostics Co., Ltd.
T：+86 371 67985313
Lynx Financial (Financial Advisor in China)
T : +86 177 01610979
Consilium Strategic Communications
Chris Gardner, Matthew
Neal, Chris Welsh
T : +44 (0)203 709 5700